Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25730022 | 0.90 | REN (0.36) | RENLIPGLIPCDPP4 | |
| SCHEMBL21106934 | 0.86 | CHRNB2 (0.34) | RENNAMPTLIPGLIPC | |
| SCHEMBL25883099 | 0.84 | HRH2 (0.38) | LIPGLIPCDPP4 | |
| SCHEMBL22793897 | 0.82 | HRH2 (0.40) | RENEPHX2LIPGLIPC | |
| SCHEMBL25728303 | 0.75 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL22526238 | 0.74 | ALDH1A1 (0.46) | EPHX2LIPGLIPC | |
| SCHEMBL22526538 | 0.74 | HRH2 (0.42) | EPHX2LIPGLIPC | |
| SCHEMBL22861849 | 0.73 | KDM4E (0.42) | EPHX2 | |
| SCHEMBL19778874 | 0.72 | L3MBTL1 (0.46) | EPHX2DPP4 | |
| SCHEMBL26753717 | 0.72 | L3MBTL1 (0.50) | EPHX2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | REN 3694/4885EPHX2 1890/4885NAMPT 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.